文献速递重症综合管理与镇静镇痛呼吸衰竭与机械通气

高强度血栓预防方案与重症新型冠状病毒肺炎患者肺栓塞的关系

Higher Intensity Thromboprophylaxis Regimens and Pulmonary Embolism in Critically Ill Coronavirus Disease 2019 Patients.
PubMed 文献 · Crit Care Med · 2020-01-01
一句话结论在机械通气的重症COVID-19患者中,高强度血栓预防方案与较低的肺栓塞发生率相关(11% vs 50%,OR 0.13),但研究为回顾性分析。

该研究回顾性分析2020年3月10日至4月30日比利时一所大学医院ICU中49例机械通气成人COVID-19患者的前瞻性收集数据,其中40例因持续低氧血症或呼吸恶化接受了CT肺动脉造影。主要终点为根据标准血栓预防(皮下依诺肝素4000国际单位每日一次)或高强度血栓预防(皮下依诺肝素4000国际单位每日两次或治疗性普通肝素)分组的肺栓塞发生率。结果显示13例(33%)诊断肺栓塞,高强度方案组肺栓塞发生率为11%(2/18),标准方案组为50%(11/22),OR 0.13(95%CI 0.02-0.69),p=0.02,校正混杂因素后差异仍显著。作者结论认为高强度血栓预防方案可能降低此类并发症的发生。

要点

  • 在40例接受CT肺动脉造影的机械通气COVID-19患者中,33%(13例)诊断肺栓塞,其中双侧6例、右肺7例。
  • 高强度血栓预防方案组肺栓塞发生率为11%(2/18),标准方案组为50%(11/22),OR 0.13(95%CI 0.02-0.69),p=0.02。
  • CT肺动脉造影当日D-二聚体对肺栓塞的预测准确度为0.90(95%CI 0.78-1.00)。
  • 肺栓塞组与非肺栓塞组ICU出院死亡率无显著差异:46%(6例)vs 52%(14例),OR 0.79(95%CI 0.24-3.26),p=0.99。
  • 作者认为高强度血栓预防方案可能降低机械通气COVID-19患者肺栓塞的发生。

适用人群与场景

  • 重症成人机械通气COVID-19患者,在持续低氧血症或呼吸恶化时接受CT肺动脉造影者纳入分析。

诊断标准与关键阈值

  • 肺栓塞诊断依据CT肺动脉造影;CT肺动脉造影指征为持续低氧血症或呼吸恶化。
  • 标准血栓预防方案:皮下依诺肝素4000国际单位每日一次。
  • 高强度血栓预防方案:皮下依诺肝素4000国际单位每日两次或治疗性普通肝素。

处置流程与药物剂量

  • 标准血栓预防:皮下依诺肝素4000国际单位每日一次。
  • 高强度血栓预防:皮下依诺肝素4000国际单位每日两次,或治疗性普通肝素。

红旗征与不能漏的情况

  • 持续低氧血症或呼吸恶化时需行CT肺动脉造影以排查肺栓塞。

研究设计与关键结果

  • 回顾性分析前瞻性收集的数据,纳入2020年3月10日至4月30日比利时一所大学医院ICU的49例机械通气成人COVID-19患者,其中40例接受CT肺动脉造影。
  • CT肺动脉造影距ICU入住中位时间7天(4-8天),距症状出现中位时间12天(9-16天)。
  • 13例(33%)诊断肺栓塞,双侧6例,右肺7例。
  • CT肺动脉造影当日D-二聚体预测肺栓塞的准确度为0.90(95%CI 0.78-1.00)。
  • 高强度血栓预防组肺栓塞发生率11%(2/18),标准方案组50%(11/22),OR 0.13(95%CI 0.02-0.69),p=0.02;校正混杂因素后差异仍显著。
  • 肺栓塞组ICU出院死亡6例(46%),非肺栓塞组死亡14例(52%),OR 0.79(95%CI 0.24-3.26),p=0.99。

证据类型、等级与局限

  • 研究类型:回顾性分析前瞻性收集的数据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为高强度血栓预防方案可能降低机械通气COVID-19患者肺栓塞的发生。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To assess the role of thromboprophylaxis regimens on the occurrence of pulmonary embolism in coronavirus disease 2019 patients.

DESIGN: Retrospective analysis of prospectively collected data on coronavirus disease 2019 patients, included between March 10, and April 30, 2020.

SETTING: ICU of an University Hospital in Belgium.

PATIENTS AND INTERVENTIONS: Critically ill adult mechanically ventilated coronavirus disease 2019 patients were eligible if they underwent a CT pulmonary angiography, as part of the routine management in case of persistent hypoxemia or respiratory deterioration. The primary endpoint of this study was the occurrence of pulmonary embolism according to the use of standard thromboprophylaxis (i.e. subcutaneous enoxaparin 4,000 international units once daily) or high regimen thromboprophylaxis (i.e. subcutaneous enoxaparin 4,000 international units bid or therapeutic unfractioned heparin).

MEASUREMENTS AND MAIN RESULTS: Of 49 mechanically ventilated coronavirus disease 2019, 40 underwent CT pulmonary angiography after a median of 7 days (4-8 d) since ICU admission and 12 days (9-16 d) days since the onset of symptoms. Thirteen patients (33%) were diagnosed of pulmonary embolism, which was bilateral in six patients and localized in the right lung in seven patients. D-dimers on the day of CT pulmonary angiography had a predictive accuracy of 0.90 (95% CIs: 0.78-1.00) for pulmonary embolism. The use of high-regimen thromboprophylaxis was associated with a lower occurrence of pulmonary embolism (2/18; 11%) than standard regimen (11/22, 50%-odds ratio 0.13 [0.02-0.69]; p = 0.02); this difference remained significant even after adjustment for confounders. Six patients with pulmonary embolism (46%) and 14 patients without pulmonary embolism (52%) died at ICU discharge (odds ratio 0.79 [0.24-3.26]; p = 0.99).

CONCLUSIONS: In this study, one third of coronavirus disease 2019 mechanically ventilated patients have a pulmonary embolism visible on CT pulmonary angiography. High regimen thromboprophylaxis may decrease the occurrence of such complication.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Taccone FS, Gevenois PA, Peluso L, et al. Higher Intensity Thromboprophylaxis Regimens and Pulmonary Embolism in Critically Ill Coronavirus Disease 2019 Patients. Crit Care Med. 2020. PMID: 32769623. doi:10.1097/CCM.0000000000004548

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。